Content Strategy Matrix

What this tool does

Pharmaceutical and healthcare content strategy is not a single discipline — it requires aligning four variables simultaneously: who you are talking to, what you are trying to achieve, how you are delivering the message, and where in the world that message will be distributed. Get any one of those wrong and you either produce a content piece that fails MLR review, reaches the wrong audience with the wrong evidence level, or breaks local regulatory rules.

This matrix makes that alignment explicit. You select one option from each of the four dimensions and the tool generates a tailored brief covering: which evidence sources to use and why, what tone and language register to adopt, what to avoid, format-specific depth and density rules, and a full MLR sign-off guide including review complexity, estimated rounds, and function-level accountability.

Core principle: The four dimensions are not independent choices. They interact. The same molecule, the same data — presented to a different audience, in a different format, in a different market — requires a completely different content strategy and a different regulatory approach.

The four dimensions

Each dimension controls a different layer of the content strategy. They are ordered by hierarchy — dimension 1 sets the master constraint that all others operate within.

Dimension 1

Audience

The master constraint. Determines what level of evidence is permissible to surface, what language register to use, and what the reader is equipped to interpret. A piece appropriate for a KOL is not appropriate for a patient — even if the underlying data is the same.

Dimension 2

Communication type

Sets the intent of the piece — which drives regulatory scrutiny level. Promotional and launch content carries the highest MLR burden. Medical/MSL scientific exchange sits in a different regulatory space. CME must present the full drug class, not just your molecule.

Dimension 3

Format

Determines density and depth of content — but never lowers the evidence standard. An infographic for HCPs requires the same quality sources as a white paper. The format shapes how evidence is presented, not which evidence is permissible.

Dimension 4

Market / Geography

Changes which regulatory label anchors the content, which epidemiological data applies, and which promotional restrictions are in force. The same piece that is fully compliant in the US may be non-compliant in India or the EU for structural reasons — not because of the data itself.

How the output is generated

The brief is assembled by cross-referencing all four selections simultaneously. Each section of the output uses a different rule set:

Evidence sources → Audience × Communication type

These two dimensions together determine what sources are appropriate. A KOL receiving a Medical/MSL exchange can receive full subgroup analyses, post-hoc data, and pharmacovigilance from EMBASE. A patient receiving disease awareness content must have all evidence translated through a regulatory or health authority body first — WHO, NIH, Cochrane plain-language summaries. Never a primary RCT citation directly.

Tone & language → Audience alone

Tone is determined entirely by who is reading. HCPs expect p-values, confidence intervals, and study names. Patients need plain language at or below an 8th-grade reading level, with empathetic and action-oriented framing. KOLs expect peer-to-peer scientific exchange with limitations acknowledged openly. Payers want economic outcomes framing — QALY, budget impact, cost-per-outcome.

What to avoid → Audience × Communication type

Avoidance rules are the intersection of who you're reaching and what you're trying to do. Off-label claims are always prohibited in promotional content. Brand mentions are prohibited in disease awareness content for patients. Comparative claims without head-to-head trial data are prohibited across all HCP promotional materials. CME content must show the full class of drugs — not just the sponsor's molecule.

Format rules → Format alone

Each format has fixed structural rules regardless of the other dimensions. A detailer always follows the unmet need → mechanism → efficacy → safety → positioning flow. A social post is always capped at 150-word captions. A white paper always requires a 1-page executive summary and minimum 8–12 cited sources. A banner never carries clinical data directly — it drives to a landing page where evidence lives.

Market guidance → Geography alone

Each market outputs: the governing regulatory body and label, the appropriate local epidemiological data sources, the relevant specialty guideline bodies, and the key restriction in force (e.g. DTC prohibition, ABPI Code, GDPR). The market layer also flags when the local label may diverge from the global reference — most critically when an Indian CDSCO dossier approves different dosing or indications than the FDA PI or EMA SmPC.

How MLR complexity is calculated

Review complexity is scored numerically by assigning risk weights to each dimension, then applying a geography multiplier. The score determines the complexity tier.

Dimension	Option	Risk weight	Rationale
Audience	Patient / General public	+3	Vulnerable population; highest language and claim scrutiny
	HCP / Payer	+2	Professionally qualified; lower vulnerability risk
	KOL / Researcher	+1	Scientific exchange context; different regulatory track
Communication type	Promotional / Product launch	+4	Highest regulatory burden; every claim must map to label
	Medical / MSL / CME / Awareness	+2	Scientific or educational intent; still requires sign-off
	Public health / Policy	+1	Lowest promotional intent; burden of disease focus
Format	Banner / Social / Detailer	+3	High visibility; claim prominence rules most stringent
	Video / Carousel / Infographic	+2	Visual claims harder to annotate; separate digital track often needed
	White paper / Podcast	+1	Lower visibility formats; references integrated naturally
Geography multiplier	Global / Multi-market	×1.3	Each market needs individual claims grid and local sign-off
	US (FDA / OPDP)	×1.2	OPDP fair balance rules; ISI block mandatory on all promos
	EU / UK	×1.1	SmPC governance; DTC prohibition adds compliance layer
	India / APAC	×1.0	Base rate; CDSCO rules apply but process is more localised

Complexity tiers

Very high (score ≥ 10): Full MLR panel review required. All functions — Medical, Regulatory, Legal, Marketing — must sign off before any distribution. Expect 3–4 rounds. Typical combinations: Patient × Promotional × Banner × US.

High (score 7–9): Medical + Legal + Regulatory sign-off mandatory. Marketing advisory. Expect 3 rounds. Typical: HCP × Product launch × Detailer × India.

Moderate (score 4–6): Medical + Regulatory required. Legal advisory, engaged if comparative claims present. Expect 2 rounds. Typical: HCP × CME × White paper × EU.

Low (score < 4): Medical review sufficient. Regulatory spot-check. Expect 1–2 rounds. Typical: KOL × Medical/MSL × White paper × India (scientific exchange context).

Key rules the matrix enforces

The audience is the ceiling, not the floor

You can always use simpler evidence for a given audience — but you cannot exceed what they are equipped to receive. A patient content piece cannot cite a primary RCT, regardless of how strong the evidence is. The regulatory label and health authority summaries are the translation layer.

Communication type determines the regulatory track

Promotional and product launch content sits on the promotional MLR track in every market. Medical/MSL scientific exchange sits on a separate track — and in most markets is exempt from promotional MLR, provided the exchange is documented formally. CME sits on a third track with its own independence requirements. These tracks must not be mixed — a detailer is always promotional even if it contains accurate scientific information.

Format shapes presentation, not permissibility

A claim that is not permitted in a white paper is not permitted in an infographic either. The format only determines how evidence is structured and how densely it appears. Reducing the number of claims shown in a social post does not lower the quality standard on those claims — they must still be approvable at the same bar as the white paper.

Geography changes the label, not just the language

The most common error in global content is assuming one regulatory label governs all markets. The CDSCO dossier, EMA SmPC, and FDA PI for the same molecule may approve different indications, different doses, different patient populations, and different safety language. The market dimension in this tool outputs the correct label anchor for each geography — and flags when local divergence is likely.

Indian data can outrank global data for local HCPs

A smaller Indian RCT (n=200–500) may carry more persuasive weight with Indian HCPs than a 10,000-patient US pivotal trial — particularly when disease presentation, dosing, or pharmacokinetics are known to differ by ethnicity. The tool flags this as a layering strategy: lead with the global trial for the headline efficacy claim, then layer Indian data for localisation and HCP credibility.

Example combinations and what changes

Example A — Highest risk

Patient× Promotional× Social post× EU

This combination is non-compliant by design in the EU — DTC advertising of prescription drugs is banned. The tool flags this immediately. Even if the content is rephrased as disease awareness, any brand association in a patient-facing social post in the EU requires careful legal review. Additionally, GDPR governs all digital data collection from the campaign.

Example B — Scientific exchange exemption

KOL / Researcher× Medical / MSL× White paper× India

This scores Low complexity. In most markets including India, formal scientific exchange between MSLs and KOLs is exempt from the promotional MLR track — provided the exchange is initiated by the HCP and documented. Full clinical dossier, subgroup analyses, and post-hoc data can be shared. No promotional sign-off required, but the exchange must be logged formally.

Example C — Global claims grid required

HCP× Product launch× Visual aid / Detailer× Global

This combination scores Very High. A single detailer cannot be used across all markets — each market's regulatory label must be checked against every claim. A claims grid is mandatory: a table mapping each efficacy and safety claim to its status (approved / not approved / not applicable) in each market in scope. The most restrictive market in the distribution set sets the ceiling for the global version.

How to use this in your workflow

Start with the brief, not the format

Always select audience and communication type before you decide on format. These two dimensions define what is permissible. Choosing the format first and then backfilling the evidence is the most common cause of MLR rejection.

Use the market dimension to catch local divergence early

Before any content goes into development, check whether the Indian CDSCO label, EMA SmPC, or local regulatory status differs from the reference market. Catching a label divergence at the brief stage costs nothing. Catching it after creative development costs significant rework time.

Use the MLR score to plan timelines, not just sign-offs

A Very High complexity brief needs 3–4 review rounds. Each round typically takes 5–10 business days. Plan backwards from distribution date: a launch detailer for the US market needs to enter MLR at least 8–10 weeks before field force deployment, not 2 weeks.

Run contrasting combinations when briefing an agency

Generate the brief for HCP-facing and patient-facing versions of the same content at the same time. Show the agency both outputs side by side. The differences in evidence level, tone, and format rules are the brief — not the brand guidelines document.

This guide is an internal reference document. All regulatory guidance should be verified against the current approved label and applicable local codes before MLR submission. This document does not constitute legal or regulatory advice.

Content Strategy & MLR Matrix — How It Works